RACHEL LIPSCOMB: Open Payments
NPI 1811657836 · FLORENCE, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,744 in 94 payments from 21 companies in 2025. Trend: 2023 $1,388 · 2024 $1,423 · 2025 $1,744
Food & beverage: $1,744
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 11 | $350 |
| ABBVIE INC. | 21 | $349 |
| PFIZER INC. | 10 | $163 |
| Lilly USA, LLC | 16 | $159 |
| Teva Pharmaceuticals USA, Inc. | 5 | $115 |
| Sumitomo Pharma America, Inc. | 5 | $78 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $62 |
| Novo Nordisk Inc | 3 | $61 |
| AstraZeneca Pharmaceuticals LP | 3 | $55 |
| Astellas Pharma US Inc | 2 | $51 |
Products named: HETLIOZ, VRAYLAR, JARDIANCE, AUSTEDO XR, REXULTI, ELIQUIS, GEMTESA, MOUNJARO.
Industry payments across KY — which companies pay providers there.
